As of 2025-07-06, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is -9.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 1,650.41 mil USD. TVTX's TTM EBITDA according to its financial statements is -181.62 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 14.3x | 13.6x |
| Forward P/E multiples | 12.7x - 14.9x | 14.4x |
| Fair Price | (30.08) - (32.86) | (32.21) |
| Upside | -300.4% - -318.9% | -314.6% |
| Date | EV/EBITDA |
| 2025-07-03 | -9.09 |
| 2025-07-02 | -9.00 |
| 2025-07-01 | -8.94 |
| 2025-06-30 | -8.98 |
| 2025-06-27 | -8.97 |
| 2025-06-26 | -9.15 |
| 2025-06-25 | -9.06 |
| 2025-06-24 | -9.20 |
| 2025-06-23 | -8.83 |
| 2025-06-20 | -8.75 |
| 2025-06-18 | -8.79 |
| 2025-06-17 | -8.64 |
| 2025-06-16 | -8.93 |
| 2025-06-13 | -8.84 |
| 2025-06-12 | -9.05 |
| 2025-06-11 | -8.85 |
| 2025-06-10 | -9.15 |
| 2025-06-09 | -9.04 |
| 2025-06-06 | -9.24 |
| 2025-06-05 | -8.95 |
| 2025-06-04 | -9.19 |
| 2025-06-03 | -9.28 |
| 2025-06-02 | -9.34 |
| 2025-05-30 | -9.09 |
| 2025-05-29 | -9.27 |
| 2025-05-28 | -9.06 |
| 2025-05-27 | -9.25 |
| 2025-05-23 | -9.49 |
| 2025-05-22 | -9.42 |
| 2025-05-21 | -9.86 |
| 2025-05-20 | -10.33 |
| 2025-05-19 | -10.07 |
| 2025-05-16 | -9.96 |
| 2025-05-15 | -12.09 |
| 2025-05-14 | -12.06 |
| 2025-05-13 | -11.99 |
| 2025-05-12 | -12.28 |
| 2025-05-09 | -11.54 |
| 2025-05-08 | -11.74 |
| 2025-05-07 | -11.64 |
| 2025-05-06 | -11.50 |
| 2025-05-05 | -12.22 |
| 2025-05-02 | -12.09 |
| 2025-05-01 | -11.90 |
| 2025-04-30 | -11.92 |
| 2025-04-29 | -11.57 |
| 2025-04-28 | -11.21 |
| 2025-04-25 | -10.71 |
| 2025-04-24 | -10.37 |
| 2025-04-23 | -9.91 |